All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your GvHD Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2022-05-09T09:49:13.000Z

What is the latest update on biomarkers for assessing GvHD?

By Marcia Rato, Addy Dullaghan, Ella Dixon
Featured
Carrie Kitko
May 9, 2022
Share:

Bookmark this article

During the 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings), the GvHD Hub was pleased to speak to Carrie L. Kitko, Vanderbilt University Medical Center, Nashville, US. We asked, What is the latest update on biomarkers for assessing GvHD?

What is the latest update on biomarkers for assessing GvHD?

Kitko begins by explaining how treatment response at Day 28 is used as a surrogate marker for long-term outcomes in clinical trials, despite limited accuracy. Kitko then discusses the Mount Sinai Acute GvHD International Consortium (MAGIC) algorithm, which can be used to estimate a patient's probability of 6-month nonrelapse mortality. Finally, Kitko talks about potential new biomarkers that were discussed at the Tandem Meetings.

More about...
Acute graft-versus-host diseaseChronic graft-versus-host diseaseTCT 2022TCT Meetings

Related articles

Add bookmark

HLA-DPB1 mismatch models after unrelated donor stem cell transplantation

In a recent letter to Haematologica, Francesca Lorentino from the Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milano, IT, and...

Oct 16, 2019
Add bookmark

HLA-DPB1 mismatch models after unrelated donor stem cell transplantation

In a recent letter to Haematologica, Francesca Lorentino from the Hematology and Bone Marrow Transplantation Unit, IRCCS San...

Oct 16, 2019
Add bookmark

EBMT 2019 | Incorporation of PT-Cy as standard-of-care prophylaxis in patients with an increased risk of GvHD

Irene García-Cadena discussed the role of incorporating PT-Cy-based prophylaxis as a standard-of-care (SoC) in HLA matched siblings or...

Apr 23, 2019
Add bookmark

EBMT 2019 | Incorporation of PT-Cy as standard-of-care prophylaxis in patients with an increased risk of GvHD

Irene García-Cadena discussed the role of incorporating PT-Cy-based prophylaxis as a...

Apr 23, 2019

Newsletter

Subscribe to get the best content related to GvHD delivered to your inbox